Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. Competitors

1,314 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GPCRStructure Therapeutics, Inc. Sponsored ADR$18.17$1.30B-4.66-51.47%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGPCRUnlock the GPCR top-analyst price target with TipRanks Premium
LXRXLexicon Pharmaceuticals$1.78$792.52M-12.2821.92%Strong BuyUnlock the LXRX analyst price target with TipRanks PremiumGPCR vs LXRXUnlock the LXRX top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$26.88$3.43B-4.98-29.67%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumGPCR vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$53.10$2.64B-17.19107.34%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumGPCR vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
SEPNSepterna, Inc.$40.02$1.90B-30.7784.94%Strong BuyUnlock the SEPN analyst price target with TipRanks PremiumGPCR vs SEPNUnlock the SEPN top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$12.20$1.58B-4.00-53.08%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGPCR vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GPCRStructure Therapeutics, Inc. Sponsored ADR18.17-18.34-50.23%
LXRXLexicon Pharmaceuticals1.780.3322.76%
VKTXViking Therapeutics26.88-9.16-25.42%
MBXMBX Biosciences, Inc.53.1025.7193.87%
SEPNSepterna, Inc.40.0216.9273.25%
KLRAKailera Therapeutics, Inc.12.20-13.80-53.08%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts